Allen T Horhota

US Patent:

20220177540, Jun 9, 2022

Filed:

Dec 10, 2021

Appl. No.:

17/548247

Inventors:

- Cambridge MA, US
Shinichiro Fuse - Cambridge MA, US
Brian Goodman - Cambridge MA, US
Allen T. Horhota - Cambridge MA, US
Raffaella Squilloni - Cambridge MA, US

International Classification:

C07K 14/725
A61K 9/51
A61K 35/17
C07K 16/28

Abstract:

Circular RNA and transfer vehicles, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes a chimeric antigen receptor (CAR). In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.

US Patent:

20230062665, Mar 2, 2023

Filed:

Dec 10, 2021

Appl. No.:

17/548241

Inventors:

- Cambridge MA, US
Alexander Wesselhoeft - Cambridge MA, US
Allen Horhota - Westford MA, US
Junghoon Yang - Cambridge MA, US

International Classification:

A61K 31/7105
A61K 47/22

Abstract:

Disclosed herein are circular RNA s and transfer vehicles, along with related compositions and methods of treatment. The circular RNAs can comprise group I intron fragments, spacers, an IRES, duplex forming regions, and/or an expression sequence, thereby having the features of improved expression, functional stability, low immunogenicity, ease of manufacturing, and/or extended half-life compared to linear RNA. Pharmaceutical compositions comprising such circular RNAs and transfer vehicles are particularly suitable for efficient protein expression in immune cells in vivo. Also disclosed are precursor RNAs and materials useful in producing the precursor or circular RNAs, which have improved circularization efficiency and/or are compatible with effective circular RNA purification methods.

US Patent:

20230058784, Feb 23, 2023

Filed:

Oct 15, 2021

Appl. No.:

17/503208

Inventors:

- Cambridge MA, US
Alexander Wesselhoeft - Cambridge MA, US
Allen Horhota - Westford MA, US
Junghoon Yang - Cambridge MA, US

International Classification:

A61K 31/7105
A61K 47/22

Abstract:

Disclosed herein are circular RNA s and transfer vehicles, along with related compositions and methods of treatment. The circular RNAs can comprise group I intron fragments, spacers, an IRES, duplex forming regions, and/or an expression sequence, thereby having the features of improved expression, functional stability, low immunogenicity, ease of manufacturing, and/or extended half-life compared to linear RNA. Pharmaceutical compositions comprising such circular RNAs and transfer vehicles are particularly suitable for efficient protein expression in immune cells in vivo. Also disclosed are precursor RNAs and materials useful in producing the precursor or circular RNAs, which have improved circularization efficiency and/or are compatible with effective circular RNA purification methods.

US Patent:

20210371494, Dec 2, 2021

Filed:

Jul 23, 2021

Appl. No.:

17/384460

Inventors:

- Cambridge MA, US
Shinichiro Fuse - Cambridge MA, US
Brian Goodman - Cambridge MA, US
Allen T. Horhota - Cambridge MA, US
Raffaella Squilloni - Cambridge MA, US

International Classification:

C07K 14/725
A61K 35/17
C07K 16/28
A61K 9/51

Abstract:

Circular RNA and transfer vehicles, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes a chimeric antigen receptor (CAR). In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.

US Patent:

20190029960, Jan 31, 2019

Filed:

Oct 12, 2018

Appl. No.:

16/158467

Inventors:

- New York NY, US
Kevin Andrew McDonnell - Lexington MA, US
Allen Thomas Horhota - Westford MA, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 9/14
A61K 38/17
A61K 47/59
A61K 47/60
A61K 9/00
A61K 47/62
A61K 9/51
A61K 47/69
A61K 47/34

Abstract:

Provided herein in part is a therapeutic nanoparticle that includes a biocompatible polymer; a polymer-EGFR ligand conjugate, wherein the EGFR ligand is covalently bound directly or through a chemical linker to the polymer, and a therapeutic agent.

US Patent:

20170224620, Aug 10, 2017

Filed:

Aug 19, 2016

Appl. No.:

15/241977

Inventors:

- New York NY, US
Kevin McDonnell - Lexington MA, US
Allen Horhota - Westford MA, US

International Classification:

A61K 9/14
A61K 38/17

Abstract:

Provided herein in part is a therapeutic nanoparticle that includes a biocompatible polymer; a polymer—EGFR ligand conjugate, wherein the EGFR ligand is covalently bound directly or through a chemical linker to the polymer, and a therapeutic agent.